Digestion · 2006 · 14 citations · 7 references
PharmacyInfectious DiseasesPharmacotherapyHepatologyImmunotherapyInflammationAntiviral PharmacotherapyAntiviral TherapyInflammatory Bowel DiseaseInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentChronic Viral HepatitisCombination Antiviral TherapyHepatitis C InfectionImmunomodulatory EffectsInterferon Alfa TherapyInterferon Alpha-2b TherapyPegylated Interferon AlfaRibavirin Therapy
We describe the case of a patient with a diagnosis of Crohn's disease and accidental infection during abdominal surgery by hepatitis C virus (HCV) who received combination therapy with pegylated interferon-alpha2b (1.5 microg/kg weekly) plus ribavirin (10.6 mg/kg daily) for histologically demonstrated chronic hepatitis C. After 48 weeks treatment, serum transaminase levels were normal and viremia (HCV RNA) was negative (end-of-treatment response); 24 weeks later (follow-up period), a sustained virological response was demonstrated. The tolerance to combination antiviral therapy was good, without intestinal symptoms of inflammatory bowel disease recurrence. We conclude that current antiviral therapies with immunomodulatory effects may be helpful and safe for patients with inflammatory bowel disease infected by hepatitis C virus.
7
Current and Emerging Infectious Risks of Blood Transfusions
Michael P. Busch, Steven Kleinman, George J. Nemo · JAMA · 2003 · 341 citations
S. Bargiggia, Douglas Thorburn, Andrea Anderloni et al. · Alimentary Pharmacology & Therapeutics · 2005 · 42 citations · Full text